nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—NR3C1—Prednisolone—chronic obstructive pulmonary disease	0.131	0.189	CbGbCtD
Mifepristone—NR3C1—Prednisone—chronic obstructive pulmonary disease	0.124	0.178	CbGbCtD
Mifepristone—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0648	0.0932	CbGbCtD
Mifepristone—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0648	0.0932	CbGbCtD
Mifepristone—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0578	0.0831	CbGbCtD
Mifepristone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0544	0.0782	CbGbCtD
Mifepristone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0367	0.0528	CbGbCtD
Mifepristone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0351	0.0504	CbGbCtD
Mifepristone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0312	0.0449	CbGbCtD
Mifepristone—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0306	0.044	CbGbCtD
Mifepristone—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0289	0.0415	CbGbCtD
Mifepristone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0183	0.0264	CbGbCtD
Mifepristone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0173	0.0249	CbGbCtD
Mifepristone—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000753	0.00305	CcSEcCtD
Mifepristone—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000751	0.00305	CcSEcCtD
Mifepristone—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00075	0.00304	CcSEcCtD
Mifepristone—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000746	0.00303	CcSEcCtD
Mifepristone—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000743	0.00301	CcSEcCtD
Mifepristone—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00074	0.003	CcSEcCtD
Mifepristone—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000738	0.00299	CcSEcCtD
Mifepristone—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000738	0.00299	CcSEcCtD
Mifepristone—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000734	0.00298	CcSEcCtD
Mifepristone—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000734	0.00298	CcSEcCtD
Mifepristone—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000729	0.00296	CcSEcCtD
Mifepristone—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000725	0.00294	CcSEcCtD
Mifepristone—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000721	0.00292	CcSEcCtD
Mifepristone—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000719	0.00292	CcSEcCtD
Mifepristone—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000712	0.00289	CcSEcCtD
Mifepristone—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000708	0.00287	CcSEcCtD
Mifepristone—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000708	0.00287	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000703	0.00285	CcSEcCtD
Mifepristone—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000698	0.00283	CcSEcCtD
Mifepristone—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000698	0.00283	CcSEcCtD
Mifepristone—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000698	0.00283	CcSEcCtD
Mifepristone—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000697	0.00283	CcSEcCtD
Mifepristone—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000693	0.00281	CcSEcCtD
Mifepristone—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000688	0.00279	CcSEcCtD
Mifepristone—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000688	0.00279	CcSEcCtD
Mifepristone—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000683	0.00277	CcSEcCtD
Mifepristone—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000669	0.00271	CcSEcCtD
Mifepristone—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000669	0.00271	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000667	0.0027	CcSEcCtD
Mifepristone—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00066	0.00268	CcSEcCtD
Mifepristone—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000659	0.00267	CcSEcCtD
Mifepristone—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000659	0.00267	CcSEcCtD
Mifepristone—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000659	0.00267	CcSEcCtD
Mifepristone—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00065	0.00264	CcSEcCtD
Mifepristone—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00065	0.00264	CcSEcCtD
Mifepristone—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00065	0.00264	CcSEcCtD
Mifepristone—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00065	0.00264	CcSEcCtD
Mifepristone—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00065	0.00264	CcSEcCtD
Mifepristone—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00065	0.00264	CcSEcCtD
Mifepristone—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000648	0.00263	CcSEcCtD
Mifepristone—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000648	0.00263	CcSEcCtD
Mifepristone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000647	0.00262	CcSEcCtD
Mifepristone—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000647	0.00262	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000645	0.00262	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000645	0.00262	CcSEcCtD
Mifepristone—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000642	0.0026	CcSEcCtD
Mifepristone—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000642	0.0026	CcSEcCtD
Mifepristone—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000637	0.00258	CcSEcCtD
Mifepristone—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000637	0.00258	CcSEcCtD
Mifepristone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000636	0.00258	CcSEcCtD
Mifepristone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000636	0.00258	CcSEcCtD
Mifepristone—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000634	0.00257	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000632	0.00256	CcSEcCtD
Mifepristone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000631	0.00256	CcSEcCtD
Mifepristone—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000623	0.00253	CcSEcCtD
Mifepristone—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000623	0.00253	CcSEcCtD
Mifepristone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000622	0.00252	CcSEcCtD
Mifepristone—Infection—Formoterol—chronic obstructive pulmonary disease	0.000619	0.00251	CcSEcCtD
Mifepristone—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000619	0.00251	CcSEcCtD
Mifepristone—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000614	0.00249	CcSEcCtD
Mifepristone—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000614	0.00249	CcSEcCtD
Mifepristone—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000613	0.00249	CcSEcCtD
Mifepristone—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000612	0.00248	CcSEcCtD
Mifepristone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000611	0.00248	CcSEcCtD
Mifepristone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000611	0.00248	CcSEcCtD
Mifepristone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00061	0.00247	CcSEcCtD
Mifepristone—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00061	0.00247	CcSEcCtD
Mifepristone—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000606	0.00246	CcSEcCtD
Mifepristone—Infection—Montelukast—chronic obstructive pulmonary disease	0.000606	0.00246	CcSEcCtD
Mifepristone—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000606	0.00246	CcSEcCtD
Mifepristone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000605	0.00245	CcSEcCtD
Mifepristone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000605	0.00245	CcSEcCtD
Mifepristone—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000603	0.00245	CcSEcCtD
Mifepristone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.0006	0.00243	CcSEcCtD
Mifepristone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000598	0.00243	CcSEcCtD
Mifepristone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000593	0.0024	CcSEcCtD
Mifepristone—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000588	0.00239	CcSEcCtD
Mifepristone—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000584	0.00237	CcSEcCtD
Mifepristone—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000582	0.00236	CcSEcCtD
Mifepristone—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000582	0.00236	CcSEcCtD
Mifepristone—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000579	0.00235	CcSEcCtD
Mifepristone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000577	0.00234	CcSEcCtD
Mifepristone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000571	0.00232	CcSEcCtD
Mifepristone—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000569	0.00231	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000568	0.0023	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000568	0.0023	CcSEcCtD
Mifepristone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000564	0.00228	CcSEcCtD
Mifepristone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000564	0.00228	CcSEcCtD
Mifepristone—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000561	0.00227	CcSEcCtD
Mifepristone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00056	0.00227	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000556	0.00225	CcSEcCtD
Mifepristone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000555	0.00225	CcSEcCtD
Mifepristone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000555	0.00225	CcSEcCtD
Mifepristone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000554	0.00225	CcSEcCtD
Mifepristone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000554	0.00225	CcSEcCtD
Mifepristone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000552	0.00224	CcSEcCtD
Mifepristone—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00055	0.00223	CcSEcCtD
Mifepristone—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000546	0.00221	CcSEcCtD
Mifepristone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000543	0.0022	CcSEcCtD
Mifepristone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000541	0.0022	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000538	0.00218	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000538	0.00218	CcSEcCtD
Mifepristone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000537	0.00218	CcSEcCtD
Mifepristone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000537	0.00218	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000536	0.00217	CcSEcCtD
Mifepristone—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000533	0.00216	CcSEcCtD
Mifepristone—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000533	0.00216	CcSEcCtD
Mifepristone—Pain—Formoterol—chronic obstructive pulmonary disease	0.000533	0.00216	CcSEcCtD
Mifepristone—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000533	0.00216	CcSEcCtD
Mifepristone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000532	0.00216	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000527	0.00214	CcSEcCtD
Mifepristone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000526	0.00213	CcSEcCtD
Mifepristone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000524	0.00213	CcSEcCtD
Mifepristone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000523	0.00212	CcSEcCtD
Mifepristone—Pain—Montelukast—chronic obstructive pulmonary disease	0.000522	0.00212	CcSEcCtD
Mifepristone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000521	0.00211	CcSEcCtD
Mifepristone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000516	0.00209	CcSEcCtD
Mifepristone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000516	0.00209	CcSEcCtD
Mifepristone—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000513	0.00208	CcSEcCtD
Mifepristone—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000513	0.00208	CcSEcCtD
Mifepristone—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000513	0.00208	CcSEcCtD
Mifepristone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000511	0.00207	CcSEcCtD
Mifepristone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000511	0.00207	CcSEcCtD
Mifepristone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000509	0.00207	CcSEcCtD
Mifepristone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000509	0.00207	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000508	0.00206	CcSEcCtD
Mifepristone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000507	0.00206	CcSEcCtD
Mifepristone—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000503	0.00204	CcSEcCtD
Mifepristone—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000503	0.00204	CcSEcCtD
Mifepristone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000499	0.00202	CcSEcCtD
Mifepristone—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000495	0.00201	CcSEcCtD
Mifepristone—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000495	0.00201	CcSEcCtD
Mifepristone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000493	0.002	CcSEcCtD
Mifepristone—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000493	0.002	CcSEcCtD
Mifepristone—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000493	0.002	CcSEcCtD
Mifepristone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000493	0.002	CcSEcCtD
Mifepristone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000491	0.00199	CcSEcCtD
Mifepristone—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000487	0.00197	CcSEcCtD
Mifepristone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000486	0.00197	CcSEcCtD
Mifepristone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000486	0.00197	CcSEcCtD
Mifepristone—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000485	0.00197	CcSEcCtD
Mifepristone—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000485	0.00197	CcSEcCtD
Mifepristone—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000484	0.00196	CcSEcCtD
Mifepristone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000482	0.00196	CcSEcCtD
Mifepristone—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000482	0.00196	CcSEcCtD
Mifepristone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000481	0.00195	CcSEcCtD
Mifepristone—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000477	0.00194	CcSEcCtD
Mifepristone—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000475	0.00193	CcSEcCtD
Mifepristone—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000467	0.0019	CcSEcCtD
Mifepristone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000465	0.00189	CcSEcCtD
Mifepristone—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000465	0.00189	CcSEcCtD
Mifepristone—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000459	0.00186	CcSEcCtD
Mifepristone—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000459	0.00186	CcSEcCtD
Mifepristone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000459	0.00186	CcSEcCtD
Mifepristone—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000454	0.00184	CcSEcCtD
Mifepristone—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00045	0.00182	CcSEcCtD
Mifepristone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000447	0.00181	CcSEcCtD
Mifepristone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000447	0.00181	CcSEcCtD
Mifepristone—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000441	0.00179	CcSEcCtD
Mifepristone—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000441	0.00179	CcSEcCtD
Mifepristone—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.00044	0.00178	CcSEcCtD
Mifepristone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000438	0.00178	CcSEcCtD
Mifepristone—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000433	0.00176	CcSEcCtD
Mifepristone—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000432	0.00175	CcSEcCtD
Mifepristone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000426	0.00173	CcSEcCtD
Mifepristone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000426	0.00173	CcSEcCtD
Mifepristone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000422	0.00171	CcSEcCtD
Mifepristone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000418	0.00169	CcSEcCtD
Mifepristone—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000416	0.00169	CcSEcCtD
Mifepristone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000412	0.00167	CcSEcCtD
Mifepristone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000412	0.00167	CcSEcCtD
Mifepristone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000404	0.00164	CcSEcCtD
Mifepristone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000403	0.00163	CcSEcCtD
Mifepristone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000396	0.00161	CcSEcCtD
Mifepristone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000396	0.00161	CcSEcCtD
Mifepristone—Rash—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00159	CcSEcCtD
Mifepristone—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00159	CcSEcCtD
Mifepristone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000392	0.00159	CcSEcCtD
Mifepristone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000392	0.00159	CcSEcCtD
Mifepristone—Headache—Formoterol—chronic obstructive pulmonary disease	0.00039	0.00158	CcSEcCtD
Mifepristone—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00039	0.00158	CcSEcCtD
Mifepristone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000389	0.00158	CcSEcCtD
Mifepristone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00157	CcSEcCtD
Mifepristone—Rash—Montelukast—chronic obstructive pulmonary disease	0.000385	0.00156	CcSEcCtD
Mifepristone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000384	0.00156	CcSEcCtD
Mifepristone—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000384	0.00156	CcSEcCtD
Mifepristone—Headache—Montelukast—chronic obstructive pulmonary disease	0.000382	0.00155	CcSEcCtD
Mifepristone—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000378	0.00153	CcSEcCtD
Mifepristone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000374	0.00152	CcSEcCtD
Mifepristone—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000373	0.00151	CcSEcCtD
Mifepristone—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.0015	CcSEcCtD
Mifepristone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.0015	CcSEcCtD
Mifepristone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00037	0.0015	CcSEcCtD
Mifepristone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00037	0.0015	CcSEcCtD
Mifepristone—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.00149	CcSEcCtD
Mifepristone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000362	0.00147	CcSEcCtD
Mifepristone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000357	0.00145	CcSEcCtD
Mifepristone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000349	0.00142	CcSEcCtD
Mifepristone—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000348	0.00141	CcSEcCtD
Mifepristone—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000347	0.00141	CcSEcCtD
Mifepristone—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000345	0.0014	CcSEcCtD
Mifepristone—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000339	0.00138	CcSEcCtD
Mifepristone—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000337	0.00137	CcSEcCtD
Mifepristone—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000313	0.00127	CcSEcCtD
Mifepristone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000305	0.00124	CcSEcCtD
Mifepristone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000302	0.00123	CcSEcCtD
Mifepristone—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.0003	0.00122	CcSEcCtD
Mifepristone—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000289	0.00117	CcSEcCtD
Mifepristone—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000279	0.00113	CcSEcCtD
Mifepristone—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000278	0.00113	CcSEcCtD
Mifepristone—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000275	0.00111	CcSEcCtD
Mifepristone—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000271	0.0011	CcSEcCtD
Mifepristone—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000268	0.00109	CcSEcCtD
Mifepristone—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000259	0.00105	CcSEcCtD
Mifepristone—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000256	0.00104	CcSEcCtD
Mifepristone—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000256	0.00104	CcSEcCtD
Mifepristone—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000255	0.00103	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000254	0.00103	CcSEcCtD
Mifepristone—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000253	0.00102	CcSEcCtD
Mifepristone—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000249	0.00101	CcSEcCtD
Mifepristone—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000994	CcSEcCtD
Mifepristone—Infection—Prednisone—chronic obstructive pulmonary disease	0.000244	0.000988	CcSEcCtD
Mifepristone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00024	0.000975	CcSEcCtD
Mifepristone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000966	CcSEcCtD
Mifepristone—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000948	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000223	0.000906	CcSEcCtD
Mifepristone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000223	0.000905	CcSEcCtD
Mifepristone—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000222	0.000899	CcSEcCtD
Mifepristone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000213	0.000864	CcSEcCtD
Mifepristone—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000213	0.000863	CcSEcCtD
Mifepristone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000213	0.000862	CcSEcCtD
Mifepristone—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000211	0.000857	CcSEcCtD
Mifepristone—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000211	0.000857	CcSEcCtD
Mifepristone—Constipation—Prednisone—chronic obstructive pulmonary disease	0.00021	0.00085	CcSEcCtD
Mifepristone—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000202	0.000819	CcSEcCtD
Mifepristone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000201	0.000813	CcSEcCtD
Mifepristone—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.000813	CcSEcCtD
Mifepristone—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000195	0.00079	CcSEcCtD
Mifepristone—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000786	CcSEcCtD
Mifepristone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000786	CcSEcCtD
Mifepristone—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000181	0.000733	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—chronic obstructive pulmonary disease	0.000178	0.00312	CbGpPWpGaD
Mifepristone—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000176	0.000713	CcSEcCtD
Mifepristone—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000703	CcSEcCtD
Mifepristone—CYP3A7—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000172	0.00301	CbGpPWpGaD
Mifepristone—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00017	0.00298	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000169	0.00297	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000168	0.00296	CbGpPWpGaD
Mifepristone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000168	0.00068	CcSEcCtD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000166	0.00292	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—MMP1—chronic obstructive pulmonary disease	0.000166	0.00292	CbGpPWpGaD
Mifepristone—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000166	0.00292	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000166	0.00291	CbGpPWpGaD
Mifepristone—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000166	0.00291	CbGpPWpGaD
Mifepristone—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000657	CcSEcCtD
Mifepristone—PGR—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000161	0.00283	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—chronic obstructive pulmonary disease	0.000161	0.00282	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—SERPINE1—chronic obstructive pulmonary disease	0.000158	0.00277	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000156	0.00274	CbGpPWpGaD
Mifepristone—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000632	CcSEcCtD
Mifepristone—Rash—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000627	CcSEcCtD
Mifepristone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000626	CcSEcCtD
Mifepristone—Headache—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000623	CcSEcCtD
Mifepristone—NR3C1—AP-1 transcription factor network—CXCL8—chronic obstructive pulmonary disease	0.00015	0.00263	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.000149	0.00262	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000149	0.00262	CbGpPWpGaD
Mifepristone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000149	0.00261	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000148	0.00259	CbGpPWpGaD
Mifepristone—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000147	0.00258	CbGpPWpGaD
Mifepristone—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000146	0.000591	CcSEcCtD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000144	0.00254	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000143	0.00252	CbGpPWpGaD
Mifepristone—CYP3A7—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000143	0.00251	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000141	0.00248	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—LEP—chronic obstructive pulmonary disease	0.000137	0.00241	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000137	0.00241	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—MMP9—chronic obstructive pulmonary disease	0.000136	0.00238	CbGpPWpGaD
Mifepristone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000134	0.00235	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000134	0.00235	CbGpPWpGaD
Mifepristone—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000132	0.00232	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—chronic obstructive pulmonary disease	0.000132	0.00232	CbGpPWpGaD
Mifepristone—CYP3A7—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000132	0.00231	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.00013	0.00228	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000128	0.00224	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000128	0.00224	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000127	0.00223	CbGpPWpGaD
Mifepristone—CYP3A7—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000125	0.00219	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000124	0.00218	CbGpPWpGaD
Mifepristone—CYP3A7—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000123	0.00216	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000122	0.00215	CbGpPWpGaD
Mifepristone—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000121	0.00212	CbGpPWpGaD
Mifepristone—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00012	0.00211	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—EGFR—chronic obstructive pulmonary disease	0.000119	0.00209	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000118	0.00208	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000115	0.00202	CbGpPWpGaD
Mifepristone—NR3C1—Endoderm Differentiation—TGFB1—chronic obstructive pulmonary disease	0.000114	0.00201	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.000114	0.002	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—TGFB1—chronic obstructive pulmonary disease	0.000112	0.00196	CbGpPWpGaD
Mifepristone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000109	0.00191	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—SERPINE1—chronic obstructive pulmonary disease	0.000108	0.00189	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000106	0.00186	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000105	0.00184	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000104	0.00183	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000103	0.00182	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000102	0.00179	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—EGFR—chronic obstructive pulmonary disease	0.000102	0.00179	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—APIP—chronic obstructive pulmonary disease	0.0001	0.00176	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	9.98e-05	0.00175	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	9.97e-05	0.00175	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	9.76e-05	0.00171	CbGpPWpGaD
Mifepristone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.73e-05	0.00171	CbGpPWpGaD
Mifepristone—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.6e-05	0.00169	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.51e-05	0.00167	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9.38e-05	0.00165	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—TP53—chronic obstructive pulmonary disease	9.2e-05	0.00162	CbGpPWpGaD
Mifepristone—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	9.01e-05	0.00158	CbGpPWpGaD
Mifepristone—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.89e-05	0.00156	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.82e-05	0.00155	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.7e-05	0.00153	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	8.68e-05	0.00152	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	8.64e-05	0.00152	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	8.45e-05	0.00148	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—IL6—chronic obstructive pulmonary disease	8.42e-05	0.00148	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	8.2e-05	0.00144	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—TP53—chronic obstructive pulmonary disease	8.11e-05	0.00142	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	7.9e-05	0.00139	CbGpPWpGaD
Mifepristone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.89e-05	0.00139	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	7.84e-05	0.00138	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	7.81e-05	0.00137	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.62e-05	0.00134	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	7.58e-05	0.00133	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	7.56e-05	0.00133	CbGpPWpGaD
Mifepristone—PGR—respiratory system—chronic obstructive pulmonary disease	7.56e-05	0.0864	CbGeAlD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—IL6—chronic obstructive pulmonary disease	7.42e-05	0.0013	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—GC—chronic obstructive pulmonary disease	7.41e-05	0.0013	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.4e-05	0.0013	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.36e-05	0.00129	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	7.31e-05	0.00128	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.26e-05	0.00127	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	7.25e-05	0.00127	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	7.25e-05	0.00127	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—CTGF—chronic obstructive pulmonary disease	7.2e-05	0.00126	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	7.19e-05	0.00126	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	7.01e-05	0.00123	CbGpPWpGaD
Mifepristone—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.94e-05	0.00122	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.89e-05	0.00121	CbGpPWpGaD
Mifepristone—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.86e-05	0.0012	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	6.86e-05	0.0012	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	6.82e-05	0.0012	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—TGFB1—chronic obstructive pulmonary disease	6.81e-05	0.0012	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.76e-05	0.00119	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—HDAC2—chronic obstructive pulmonary disease	6.71e-05	0.00118	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.67e-05	0.00117	CbGpPWpGaD
Mifepristone—PGR—connective tissue—chronic obstructive pulmonary disease	6.65e-05	0.0761	CbGeAlD
Mifepristone—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.65e-05	0.00117	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	6.6e-05	0.00116	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	6.56e-05	0.00115	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	6.47e-05	0.00114	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	6.47e-05	0.00114	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	6.41e-05	0.00113	CbGpPWpGaD
Mifepristone—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.41e-05	0.00113	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—TNF—chronic obstructive pulmonary disease	6.36e-05	0.00112	CbGpPWpGaD
Mifepristone—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.32e-05	0.00111	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	6.16e-05	0.00108	CbGpPWpGaD
Mifepristone—PGR—smooth muscle tissue—chronic obstructive pulmonary disease	6.08e-05	0.0696	CbGeAlD
Mifepristone—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.01e-05	0.00106	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	5.96e-05	0.00105	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	5.94e-05	0.00104	CbGpPWpGaD
Mifepristone—ABCC1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	5.91e-05	0.00104	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	5.85e-05	0.00103	CbGpPWpGaD
Mifepristone—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.77e-05	0.00101	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.69e-05	0.000999	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	5.5e-05	0.000965	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	5.49e-05	0.000964	CbGpPWpGaD
Mifepristone—AR—Gene Expression—CTGF—chronic obstructive pulmonary disease	5.48e-05	0.000963	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	5.47e-05	0.000961	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	5.45e-05	0.000957	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	5.43e-05	0.000954	CbGpPWpGaD
Mifepristone—AR—connective tissue—chronic obstructive pulmonary disease	5.3e-05	0.0606	CbGeAlD
Mifepristone—AR—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	5.19e-05	0.000912	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	5.16e-05	0.000906	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—IL6—chronic obstructive pulmonary disease	5.13e-05	0.000901	CbGpPWpGaD
Mifepristone—AR—Gene Expression—HDAC2—chronic obstructive pulmonary disease	5.11e-05	0.000897	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	5.09e-05	0.000894	CbGpPWpGaD
Mifepristone—AR—bronchus—chronic obstructive pulmonary disease	4.95e-05	0.0567	CbGeAlD
Mifepristone—AR—smooth muscle tissue—chronic obstructive pulmonary disease	4.85e-05	0.0554	CbGeAlD
Mifepristone—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.81e-05	0.000845	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.8e-05	0.000844	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.74e-05	0.000833	CbGpPWpGaD
Mifepristone—ABCC1—bronchus—chronic obstructive pulmonary disease	4.71e-05	0.0538	CbGeAlD
Mifepristone—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	4.67e-05	0.000821	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.44e-05	0.000779	CbGpPWpGaD
Mifepristone—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.42e-05	0.000776	CbGpPWpGaD
Mifepristone—CYP3A5—respiratory system—chronic obstructive pulmonary disease	4.39e-05	0.0503	CbGeAlD
Mifepristone—NR3C1—respiratory system—chronic obstructive pulmonary disease	4.36e-05	0.0499	CbGeAlD
Mifepristone—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.36e-05	0.000766	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.36e-05	0.000766	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.34e-05	0.000763	CbGpPWpGaD
Mifepristone—ABCC1—trachea—chronic obstructive pulmonary disease	4.23e-05	0.0483	CbGeAlD
Mifepristone—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.19e-05	0.000736	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—CTGF—chronic obstructive pulmonary disease	4.16e-05	0.00073	CbGpPWpGaD
Mifepristone—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.13e-05	0.000726	CbGpPWpGaD
Mifepristone—ABCC1—Disease—HDAC2—chronic obstructive pulmonary disease	4.06e-05	0.000714	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.05e-05	0.000712	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.05e-05	0.000711	CbGpPWpGaD
Mifepristone—PGR—lung—chronic obstructive pulmonary disease	4.01e-05	0.0459	CbGeAlD
Mifepristone—ABCC1—Metabolism—GCLC—chronic obstructive pulmonary disease	4e-05	0.000703	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	3.94e-05	0.000692	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—HDAC2—chronic obstructive pulmonary disease	3.88e-05	0.000681	CbGpPWpGaD
Mifepristone—NR3C1—connective tissue—chronic obstructive pulmonary disease	3.84e-05	0.0439	CbGeAlD
Mifepristone—ABCC1—Disease—KL—chronic obstructive pulmonary disease	3.78e-05	0.000663	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.74e-05	0.000657	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.73e-05	0.000655	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CTGF—chronic obstructive pulmonary disease	3.65e-05	0.000641	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.63e-05	0.000637	CbGpPWpGaD
Mifepristone—NR3C1—bronchus—chronic obstructive pulmonary disease	3.59e-05	0.041	CbGeAlD
Mifepristone—ABCC1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.55e-05	0.000623	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.53e-05	0.00062	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	3.53e-05	0.000619	CbGpPWpGaD
Mifepristone—NR3C1—smooth muscle tissue—chronic obstructive pulmonary disease	3.51e-05	0.0402	CbGeAlD
Mifepristone—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	3.49e-05	0.000613	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.42e-05	0.0006	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	3.37e-05	0.000592	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.37e-05	0.000591	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.34e-05	0.000587	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	3.32e-05	0.000584	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	3.28e-05	0.000576	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.28e-05	0.000576	CbGpPWpGaD
Mifepristone—NR3C1—trachea—chronic obstructive pulmonary disease	3.22e-05	0.0369	CbGeAlD
Mifepristone—AR—lung—chronic obstructive pulmonary disease	3.2e-05	0.0366	CbGeAlD
Mifepristone—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	3.19e-05	0.000559	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.09e-05	0.000542	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.04e-05	0.000534	CbGpPWpGaD
Mifepristone—ABCC1—lung—chronic obstructive pulmonary disease	3.04e-05	0.0347	CbGeAlD
Mifepristone—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.94e-05	0.000515	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	2.93e-05	0.000515	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.92e-05	0.000514	CbGpPWpGaD
Mifepristone—ABCC1—Disease—ERBB3—chronic obstructive pulmonary disease	2.83e-05	0.000497	CbGpPWpGaD
Mifepristone—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.81e-05	0.000494	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.81e-05	0.000493	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.77e-05	0.000486	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.72e-05	0.000477	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.69e-05	0.000472	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.64e-05	0.000463	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.58e-05	0.000453	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.55e-05	0.000448	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	2.52e-05	0.000443	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	2.51e-05	0.000441	CbGpPWpGaD
Mifepristone—AR—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	2.5e-05	0.000439	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.45e-05	0.00043	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.45e-05	0.000429	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.41e-05	0.000424	CbGpPWpGaD
Mifepristone—ABCC1—Disease—NOS2—chronic obstructive pulmonary disease	2.36e-05	0.000415	CbGpPWpGaD
Mifepristone—ABCB1—respiratory system—chronic obstructive pulmonary disease	2.33e-05	0.0267	CbGeAlD
Mifepristone—CYP3A5—lung—chronic obstructive pulmonary disease	2.33e-05	0.0267	CbGeAlD
Mifepristone—NR3C1—lung—chronic obstructive pulmonary disease	2.32e-05	0.0265	CbGeAlD
Mifepristone—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	2.3e-05	0.000404	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.25e-05	0.000395	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.23e-05	0.000392	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	2.21e-05	0.000389	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.17e-05	0.000382	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.13e-05	0.000375	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.13e-05	0.000374	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.12e-05	0.000373	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.04e-05	0.000358	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.02e-05	0.000355	CbGpPWpGaD
Mifepristone—ABCC1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.99e-05	0.000349	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.93e-05	0.000338	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.9e-05	0.000334	CbGpPWpGaD
Mifepristone—ABCC1—Disease—NOS3—chronic obstructive pulmonary disease	1.9e-05	0.000333	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	1.9e-05	0.000333	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.82e-05	0.000319	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.81e-05	0.000317	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.79e-05	0.000315	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.77e-05	0.000311	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.75e-05	0.000306	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.74e-05	0.000305	CbGpPWpGaD
Mifepristone—ABCB1—trachea—chronic obstructive pulmonary disease	1.73e-05	0.0197	CbGeAlD
Mifepristone—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.69e-05	0.000296	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—ALB—chronic obstructive pulmonary disease	1.66e-05	0.000292	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.64e-05	0.000288	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.63e-05	0.000287	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.63e-05	0.000286	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.6e-05	0.000281	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.59e-05	0.000279	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.54e-05	0.000271	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.51e-05	0.000265	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.47e-05	0.000258	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	1.45e-05	0.000255	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	1.39e-05	0.000244	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.35e-05	0.000236	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.34e-05	0.000234	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.32e-05	0.000232	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.32e-05	0.000231	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.26e-05	0.000221	CbGpPWpGaD
Mifepristone—ABCC1—Disease—TGFB1—chronic obstructive pulmonary disease	1.26e-05	0.00022	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.24e-05	0.000218	CbGpPWpGaD
Mifepristone—ABCB1—lung—chronic obstructive pulmonary disease	1.24e-05	0.0142	CbGeAlD
Mifepristone—ABCC1—Disease—EGFR—chronic obstructive pulmonary disease	1.23e-05	0.000216	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.23e-05	0.000215	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.19e-05	0.000208	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.17e-05	0.000206	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.16e-05	0.000204	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.16e-05	0.000203	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.11e-05	0.000195	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.1e-05	0.000192	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.07e-05	0.000188	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	1.05e-05	0.000184	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.01e-05	0.000178	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	1e-05	0.000176	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.86e-06	0.000173	CbGpPWpGaD
Mifepristone—ABCC1—Disease—IL6—chronic obstructive pulmonary disease	9.46e-06	0.000166	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.23e-06	0.000144	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.11e-06	0.000142	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	7.91e-06	0.000139	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	7.56e-06	0.000133	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.56e-06	0.000133	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	7.45e-06	0.000131	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.17e-06	0.000126	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.13e-06	0.000125	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	4.87e-06	8.55e-05	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	4.66e-06	8.18e-05	CbGpPWpGaD
